Recent Research Analysts’ Ratings Changes for Vera Therapeutics (VERA)

Vera Therapeutics (NASDAQ: VERA) recently received a number of ratings updates from brokerages and research firms:

• 6/3/2025 – Vera Therapeutics had its “outperform” rating reaffirmed by analysts at Scotiabank.
• 6/3/2025 – Vera Therapeutics had its “buy” rating reaffirmed by analysts at Guggenheim.
• 6/2/2025 – Vera Therapeutics was given a new $65.00 price target on by analysts at Scotiabank. They now have a “sector outperform” rating on the stock.
• 6/2/2025 – Vera Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $85.00 price target on the stock, up previously from $75.00.
• 5/7/2025 – Vera Therapeutics had its price target lowered by analysts at Cantor Fitzgerald from $107.00 to $100.00. They now have an “overweight” rating on the stock.
• 5/7/2025 – Vera Therapeutics had its price target lowered by analysts at Wedbush from $34.00 to $26.00. They now have a “neutral” rating on the stock.
• 5/5/2025 – Vera Therapeutics is now covered by analysts at HC Wainwright. They set a “buy” rating and a $75.00 price target on the stock.

Vera Therapeutics Trading Up 3.8%

VERA traded up $0.79 during mid-day trading on Monday, hitting $21.65. 1,804,126 shares of the stock were exchanged, compared to its average volume of 962,136. The firm’s fifty day moving average is $22.49 and its two-hundred day moving average is $29.51. Vera Therapeutics, Inc. has a 1-year low of $18.53 and a 1-year high of $51.61. The company has a market cap of $1.38 billion, a PE ratio of -7.22 and a beta of 1.13. The company has a current ratio of 27.68, a quick ratio of 27.68 and a debt-to-equity ratio of 0.10.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). During the same quarter in the previous year, the business posted ($0.56) EPS. Equities analysts forecast that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Institutional Trading of Vera Therapeutics

Several hedge funds have recently added to or reduced their stakes in VERA. Huntington National Bank purchased a new position in shares of Vera Therapeutics in the 4th quarter valued at about $26,000. AlphaQuest LLC acquired a new position in Vera Therapeutics in the fourth quarter valued at approximately $34,000. GF Fund Management CO. LTD. purchased a new position in Vera Therapeutics in the fourth quarter valued at approximately $56,000. Quarry LP increased its stake in Vera Therapeutics by 25.0% in the first quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $60,000 after purchasing an additional 500 shares during the last quarter. Finally, Summit Investment Advisors Inc. raised its holdings in Vera Therapeutics by 16.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company’s stock worth $196,000 after purchasing an additional 639 shares in the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.